5414x » | FRESH |

: A refined commercial strategy identified high-priority opportunities in applied and research markets worth an estimated $13 to $14 billion .

The full text and detailed report of this "paper" (regulatory announcement) include the following key sections and financial highlights:

Co-founder and CEO announced he will step down from his role and the board by the end of 2026. The full regulatory document can be accessed through

: Completed a programme resulting in an approximately 5% reduction in workforce to reallocate capital to growth areas.

The full regulatory document can be accessed through the London Stock Exchange or financial news platforms like ADVFN . Interim results for the 6 months ended 30 June 25 Gross Profit : £61

: Continued advancement in national programs like NIHR Bioresource. Strategic and Operational Developments

: £72.1 million, a 22.1% increase compared to H1 2024 (£59.0 million). Gross Profit : £61.4 million, up 24% year-on-year. Gross Profit : £61.4 million

: £12.9 million (+27.4%), supported by synthetic biology.